goat anti hlamp 2  (Santa Cruz Biotechnology)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    goat anti rabbit IgG B
    Description:
    supplied at 200 µg in 0 5 ml volume pre adsorbed biotin conjugated secondary antibody recommended for use in immunohistochemical staining recommended dilution range 1 100 1 400
    Catalog Number:
    SC-2040
    Price:
    None
    Category:
    Antibodies Conventional Secondary IgGs goat anti rabbit IgG B
    Buy from Supplier


    Structured Review

    Santa Cruz Biotechnology goat anti hlamp 2
    Development of <t>anti-hLAMP-2</t> ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.
    supplied at 200 µg in 0 5 ml volume pre adsorbed biotin conjugated secondary antibody recommended for use in immunohistochemical staining recommended dilution range 1 100 1 400
    https://www.bioz.com/result/goat anti hlamp 2/product/Santa Cruz Biotechnology
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti hlamp 2 - by Bioz Stars, 2021-09
    99/100 stars

    Images

    1) Product Images from "High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Journal: Journal of the American Society of Nephrology : JASN

    doi: 10.1681/ASN.2011090920

    Development of anti-hLAMP-2 ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.
    Figure Legend Snippet: Development of anti-hLAMP-2 ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Recombinant, Positive Control, Binding Assay, Derivative Assay

    Antibodies to hLAMP-2 in patients with AAV. (A) ELISA results from patients presenting with active piFNGN/AAV from Vienna ( n =14), Groningen ( n =44), and Cambridge ( n =33). The upper limit of normal is 29 and the shaded area between 22 and 29 indicates borderline. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those without anti-hLAMP-2 antibodies are shown in green. Both ELISA and IIF assays were negative in sera in green with positive ELISA. (B) None of the 30 controls from Vienna with various types of renal disease were judged to have anti-hLAMP-2 antibodies, although 4 patients had isolated positive ELISA with negative Western blots and IIF assays. Two of the 21 SLE patients (9.5%) had anti-hLAMP-2 antibodies and an additional 2 patients had positive ELISA not confirmed by the other two assays. (C) Proportion of patients the Vienna, Groningen, and Cambridge cohorts with active piFNGN/AAV with antibodies to LAMP-2. Results are shown separately for untreated patients at presentation, patients presenting after immunosuppressive treatment had been started, and sera taken during relapse. The overall frequency of antibodies to LAMP-2 at presentation was 82% and was higher in untreated patients than those already on treatment. This difference was significant for the whole group ( P =0.0071, Fisher's exact text) and for the Groningen cohort ( P =0.0236, Fisher’s exact test).
    Figure Legend Snippet: Antibodies to hLAMP-2 in patients with AAV. (A) ELISA results from patients presenting with active piFNGN/AAV from Vienna ( n =14), Groningen ( n =44), and Cambridge ( n =33). The upper limit of normal is 29 and the shaded area between 22 and 29 indicates borderline. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those without anti-hLAMP-2 antibodies are shown in green. Both ELISA and IIF assays were negative in sera in green with positive ELISA. (B) None of the 30 controls from Vienna with various types of renal disease were judged to have anti-hLAMP-2 antibodies, although 4 patients had isolated positive ELISA with negative Western blots and IIF assays. Two of the 21 SLE patients (9.5%) had anti-hLAMP-2 antibodies and an additional 2 patients had positive ELISA not confirmed by the other two assays. (C) Proportion of patients the Vienna, Groningen, and Cambridge cohorts with active piFNGN/AAV with antibodies to LAMP-2. Results are shown separately for untreated patients at presentation, patients presenting after immunosuppressive treatment had been started, and sera taken during relapse. The overall frequency of antibodies to LAMP-2 at presentation was 82% and was higher in untreated patients than those already on treatment. This difference was significant for the whole group ( P =0.0071, Fisher's exact text) and for the Groningen cohort ( P =0.0236, Fisher’s exact test).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Isolation, Western Blot

    Indirect immunofluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface (ldlD/hLAMP-2H). (A) ldlD cells were transfected with full-length hLAMP-2 cDNA with a tyrosine to histidine mutation in the cytoplasmic lysosomal retrieval signal. Stable transfectants were sorted by flow cytometry for uniform expression of the transgene and stained with monoclonal (CD3) and polyclonal (932B) antibodies to hLAMP-2 generated by M. Fukuda as well as commercially available monoclonal (H4B4) and polyclonal anti-LAMP-2 antibodies (SCN17 and Abnova). All of the antibodies bound to hLAMP-2 on the surface of nonpermeabilized transfected cells (np). The commercial anti-hLAMP-2 cross-reacted with hamster LAMP-2 in transfected and untransfected cells especially after permeabilization (p). CD3 and 932B were the only antibodies that did not cross-react with hamster LAMP-2. A polyclonal antibody to rat LAMP-2 (Zymed Laboratories) and secondary antibody alone fail to detect either human or hamster LAMP-2. (B) FACS analysis of ldlD/hLAMP-2H cells and control ldlD cells stained with H4B4, a mAb to hLAMP-2 that cross-reacts with hamster LAMP-2. Surface expression of hLAMP-2 is detected only in transfected cells, whereas intracellular staining of native hamster LAMP-2 is apparent after permeabilization with saponin. (C) The sensitivity of the IIF assay for antibodies to hLAMP-2 assessed from doubling dilutions (1:50 to 1:800) of the standard positive control (Stand Co) compared with binding of monoclonal anti-hLAMP-2 antibody (H4B4; pos Co) and negative control serum (neg Co). IgG binding to ldlD/hLAMP-2H cells decreases progressively in titers > 1:100 and becomes negative at 1:400, which is 10-fold higher than the standard assay dilution of 1:40.
    Figure Legend Snippet: Indirect immunofluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface (ldlD/hLAMP-2H). (A) ldlD cells were transfected with full-length hLAMP-2 cDNA with a tyrosine to histidine mutation in the cytoplasmic lysosomal retrieval signal. Stable transfectants were sorted by flow cytometry for uniform expression of the transgene and stained with monoclonal (CD3) and polyclonal (932B) antibodies to hLAMP-2 generated by M. Fukuda as well as commercially available monoclonal (H4B4) and polyclonal anti-LAMP-2 antibodies (SCN17 and Abnova). All of the antibodies bound to hLAMP-2 on the surface of nonpermeabilized transfected cells (np). The commercial anti-hLAMP-2 cross-reacted with hamster LAMP-2 in transfected and untransfected cells especially after permeabilization (p). CD3 and 932B were the only antibodies that did not cross-react with hamster LAMP-2. A polyclonal antibody to rat LAMP-2 (Zymed Laboratories) and secondary antibody alone fail to detect either human or hamster LAMP-2. (B) FACS analysis of ldlD/hLAMP-2H cells and control ldlD cells stained with H4B4, a mAb to hLAMP-2 that cross-reacts with hamster LAMP-2. Surface expression of hLAMP-2 is detected only in transfected cells, whereas intracellular staining of native hamster LAMP-2 is apparent after permeabilization with saponin. (C) The sensitivity of the IIF assay for antibodies to hLAMP-2 assessed from doubling dilutions (1:50 to 1:800) of the standard positive control (Stand Co) compared with binding of monoclonal anti-hLAMP-2 antibody (H4B4; pos Co) and negative control serum (neg Co). IgG binding to ldlD/hLAMP-2H cells decreases progressively in titers > 1:100 and becomes negative at 1:400, which is 10-fold higher than the standard assay dilution of 1:40.

    Techniques Used: Immunofluorescence, Stable Transfection, Expressing, Transfection, Mutagenesis, Flow Cytometry, Cytometry, Staining, Generated, FACS, Positive Control, Binding Assay, Negative Control

    Evaluation of assays for antibodies to LAMP-2. (A) ELISA results from a panel of sera from 78 healthy controls were used to derive the mean ± SD for this group and the 95% confidence limit of the upper limit of normal for the assay, which was established at 29 U. Six controls had positive ELISA with negative Western blots and IIF assays. (B) ELISA results of the data shown in A. The upper limit of normal in the assay is 29 U. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those in which positive ELISA was not confirmed because ELISA and IIF assays were negative are in green. (C) Measurement of antibodies to hLAMP-2 by ELISA and Western blot using hLAMP-2/GST FP and IIF on ldlD/hLAMP-2H cells was compared using a panel of 41 sera selected to cover a range of positive and negative values. The panel consisted of 16 sera from patients with AAV (11 with active disease and 5 in remission), 15 controls with other renal diseases, and 10 healthy controls. The assays were graded positive (red), low positive (Western and IIF), borderline (ELISA) (orange), or negative (green). The figure illustrates the strong concordance among results from the three assays. Sera were considered to have antibodies to LAMP-2 when ≥2 assays were positive. Abbreviations: TX, renal transplant; MGN, membranous nephropathy; IgA GN, IgA nephropathy; MPGN, membranoproliferative GN; TIN, tubulointerstitial nephritis.
    Figure Legend Snippet: Evaluation of assays for antibodies to LAMP-2. (A) ELISA results from a panel of sera from 78 healthy controls were used to derive the mean ± SD for this group and the 95% confidence limit of the upper limit of normal for the assay, which was established at 29 U. Six controls had positive ELISA with negative Western blots and IIF assays. (B) ELISA results of the data shown in A. The upper limit of normal in the assay is 29 U. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those in which positive ELISA was not confirmed because ELISA and IIF assays were negative are in green. (C) Measurement of antibodies to hLAMP-2 by ELISA and Western blot using hLAMP-2/GST FP and IIF on ldlD/hLAMP-2H cells was compared using a panel of 41 sera selected to cover a range of positive and negative values. The panel consisted of 16 sera from patients with AAV (11 with active disease and 5 in remission), 15 controls with other renal diseases, and 10 healthy controls. The assays were graded positive (red), low positive (Western and IIF), borderline (ELISA) (orange), or negative (green). The figure illustrates the strong concordance among results from the three assays. Sera were considered to have antibodies to LAMP-2 when ≥2 assays were positive. Abbreviations: TX, renal transplant; MGN, membranous nephropathy; IgA GN, IgA nephropathy; MPGN, membranoproliferative GN; TIN, tubulointerstitial nephritis.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Western Blot

    cDNA constructs, generation, and quality control of recombinant hLAMP-2. (A) Representation of cDNA encoding hLAMP-2A with the 28 amino acid leader peptide (LP), 347 amino acid extracellular domain, 24 amino acid transmembrane domain (TM), and 11 amino acid cytoplasmic domain (Cytopl). The two extracellular domain constructs were utilized to express soluble hLAMP-2 in E. coli (hLAMP-2/GST) and mammalian cells (hLAMP-2sol). Both contain the leader peptide but not the transmembrane domain or cytoplasmic tail. hLAMP-2sol expressed in mammalian cells results in an appropriately glycosylated soluble protein exported into the culture supernatant via the default secretory pathway in mammalian cells. The hLAMP-2 cytoplasmic tail contains the signal that directs its retrieval from the plasma membrane to lysosomes. The critical tyrosine was mutated to a histidine in hLAMP-2H (Y/H), which targets it to the plasma membrane when expressed in ldlD cells. (B) Purified hLAMP-2/GST runs as a single 65-kD band on SDS-PAGE and silver stain. Fractions of high purity were pooled and identity of hLAMP-2 was confirmed with an antibody reactive with hLAMP-2 only. (C) Purified hLAMP-2/GST (10 μg/ml) was separated by SDS-PAGE and transferred onto PVDF before probing with specific antibodies to hLAMP-2 (932b), which bound exclusively to the fusion protein. Antibody to GST (anti-GST) recognized both fusion protein and free GST. A human serum (1:100 dilution) containing anti-hLAMP-2 antibodies (Pat. 6) also bound the fusion protein, whereas serum from a healthy control (Healthy Co 50) did not. Serum from a patient with renal disease (Dis. Co 8) contained antibodies to GST. Secondary antibodies alone were negative (anti-human, anti-rabbit). (D) Sensitivity of the Western blot was assessed from doubling dilutions (1:50 to 1:400) of the standard positive control (Stand pos Co) used for all assays. This also confirmed the optimal binding/background ratio was 1:100.
    Figure Legend Snippet: cDNA constructs, generation, and quality control of recombinant hLAMP-2. (A) Representation of cDNA encoding hLAMP-2A with the 28 amino acid leader peptide (LP), 347 amino acid extracellular domain, 24 amino acid transmembrane domain (TM), and 11 amino acid cytoplasmic domain (Cytopl). The two extracellular domain constructs were utilized to express soluble hLAMP-2 in E. coli (hLAMP-2/GST) and mammalian cells (hLAMP-2sol). Both contain the leader peptide but not the transmembrane domain or cytoplasmic tail. hLAMP-2sol expressed in mammalian cells results in an appropriately glycosylated soluble protein exported into the culture supernatant via the default secretory pathway in mammalian cells. The hLAMP-2 cytoplasmic tail contains the signal that directs its retrieval from the plasma membrane to lysosomes. The critical tyrosine was mutated to a histidine in hLAMP-2H (Y/H), which targets it to the plasma membrane when expressed in ldlD cells. (B) Purified hLAMP-2/GST runs as a single 65-kD band on SDS-PAGE and silver stain. Fractions of high purity were pooled and identity of hLAMP-2 was confirmed with an antibody reactive with hLAMP-2 only. (C) Purified hLAMP-2/GST (10 μg/ml) was separated by SDS-PAGE and transferred onto PVDF before probing with specific antibodies to hLAMP-2 (932b), which bound exclusively to the fusion protein. Antibody to GST (anti-GST) recognized both fusion protein and free GST. A human serum (1:100 dilution) containing anti-hLAMP-2 antibodies (Pat. 6) also bound the fusion protein, whereas serum from a healthy control (Healthy Co 50) did not. Serum from a patient with renal disease (Dis. Co 8) contained antibodies to GST. Secondary antibodies alone were negative (anti-human, anti-rabbit). (D) Sensitivity of the Western blot was assessed from doubling dilutions (1:50 to 1:400) of the standard positive control (Stand pos Co) used for all assays. This also confirmed the optimal binding/background ratio was 1:100.

    Techniques Used: Construct, Recombinant, Purification, SDS Page, Silver Staining, Western Blot, Positive Control, Binding Assay

    ANCA and anti-hLAMP-2 antibody titers in patients with AAV. (A and B) Sequential ANCA titers expressed as median and interquartile range in the 43 patients in the Groningen cohort followed for 12 months. ANCA titers decreased rapidly after the induction of treatment. The patients are separated into those who had PR3-ANCA ( n =25; A and C) and MPO-ANCA ( n =18; B and D). (C and D) Sequential titers of antibodies to hLAMP-2 measured by ELISA in the 43 patients in the Groningen cohort followed for 12 months. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. The patients are separated into those who had PR3-ANCA ( n =25) and MPO-ANCA ( n =18). Anti-hLAMP-2 antibodies became undetectable in
    Figure Legend Snippet: ANCA and anti-hLAMP-2 antibody titers in patients with AAV. (A and B) Sequential ANCA titers expressed as median and interquartile range in the 43 patients in the Groningen cohort followed for 12 months. ANCA titers decreased rapidly after the induction of treatment. The patients are separated into those who had PR3-ANCA ( n =25; A and C) and MPO-ANCA ( n =18; B and D). (C and D) Sequential titers of antibodies to hLAMP-2 measured by ELISA in the 43 patients in the Groningen cohort followed for 12 months. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. The patients are separated into those who had PR3-ANCA ( n =25) and MPO-ANCA ( n =18). Anti-hLAMP-2 antibodies became undetectable in

    Techniques Used: Enzyme-linked Immunosorbent Assay

    Related Articles

    Incubation:

    Article Title: CFTR-mediated anion secretion in parathyroid hormone-treated Caco-2 cells is associated with PKA and PI3K phosphorylation but not intracellular pH changes or Na+/K+-ATPase abundance
    Article Snippet: .. Thereafter, cells were washed with PBS and incubated with secondary antibody, i.e., goat anti-rabbit IgG conjugated with biotin (catalog no. Sc-2040; Santa Cruz Biotechnology), for 1 h at room temperature, followed by 1 h incubation with streptavidin-horseradish peroxidase (catalog no. SA10001; Invitrogen, CA, USA). ..

    Article Title: Control of Skeletal Muscle Atrophy Associated to Cancer or Corticosteroids by Ceramide Kinase
    Article Snippet: .. After washing with PBST, the blots were incubated with goat anti-rabbit or goat anti-mouse or bovine anti-goat horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 1:10,000/1:5000 dilution (1 h at room temperature) and developed as in [ ], using ECL Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK), high performance chemiluminescence film (GE Healthcare, Buckinghamshire, UK) or Chemidoc (Amersham, Healthcare, Buckinghamshire, UK). ..

    Article Title: The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs
    Article Snippet: .. Immunofluorescence Staining and Confocal Microscopy Immunofluorescent stainings of 4% PFA-fixed BCSCs were performed as follows: primary Abs goat anti-CXCL1 (R & D Systems Cat# AF275, RRID:AB_355288 ), rabbit anti-OPN (Abcam Cat# ab14175, RRID:AB_2194831 ), goat anti-TRAIL (Santa Cruz Biotechnology Cat# sc-6079, RRID:AB_2205918 ), and mouse anti-TWIST1 (Abcam Cat# ab50887, RRID:AB_883294 ) were incubated overnight at 4°C, followed by incubation with Alexa Fluor 633 anti-goat IgG (Thermo Fisher Scientific Cat# A-21082, RRID:AB_2535739 ), Alexa Fluor 488 anti-rabbit IgG (Thermo Fisher Scientific Cat# A32731, RRID:AB_2633280 ), or Alexa Fluor 594 anti-mouse IgG (Molecular Probes Cat# A-11005, RRID:AB_141372) for 2 h at room temperature. ..

    Article Title: Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren’s Syndrome-Related Lymphoma?
    Article Snippet: .. The blots were washed thrice for 5 min each time, followed by incubation with anti-rabbit IgG secondary goat antibody (Santa Cruz Biotechnology) or anti-mouse IgG secondary goat antibody conjugated to horseradish peroxidase at 1:2.000 dilution (Santa Cruz Biotechnology). ..

    Western Blot:

    Article Title: Control of Skeletal Muscle Atrophy Associated to Cancer or Corticosteroids by Ceramide Kinase
    Article Snippet: .. After washing with PBST, the blots were incubated with goat anti-rabbit or goat anti-mouse or bovine anti-goat horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 1:10,000/1:5000 dilution (1 h at room temperature) and developed as in [ ], using ECL Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK), high performance chemiluminescence film (GE Healthcare, Buckinghamshire, UK) or Chemidoc (Amersham, Healthcare, Buckinghamshire, UK). ..

    Immunofluorescence:

    Article Title: The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs
    Article Snippet: .. Immunofluorescence Staining and Confocal Microscopy Immunofluorescent stainings of 4% PFA-fixed BCSCs were performed as follows: primary Abs goat anti-CXCL1 (R & D Systems Cat# AF275, RRID:AB_355288 ), rabbit anti-OPN (Abcam Cat# ab14175, RRID:AB_2194831 ), goat anti-TRAIL (Santa Cruz Biotechnology Cat# sc-6079, RRID:AB_2205918 ), and mouse anti-TWIST1 (Abcam Cat# ab50887, RRID:AB_883294 ) were incubated overnight at 4°C, followed by incubation with Alexa Fluor 633 anti-goat IgG (Thermo Fisher Scientific Cat# A-21082, RRID:AB_2535739 ), Alexa Fluor 488 anti-rabbit IgG (Thermo Fisher Scientific Cat# A32731, RRID:AB_2633280 ), or Alexa Fluor 594 anti-mouse IgG (Molecular Probes Cat# A-11005, RRID:AB_141372) for 2 h at room temperature. ..

    Staining:

    Article Title: The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs
    Article Snippet: .. Immunofluorescence Staining and Confocal Microscopy Immunofluorescent stainings of 4% PFA-fixed BCSCs were performed as follows: primary Abs goat anti-CXCL1 (R & D Systems Cat# AF275, RRID:AB_355288 ), rabbit anti-OPN (Abcam Cat# ab14175, RRID:AB_2194831 ), goat anti-TRAIL (Santa Cruz Biotechnology Cat# sc-6079, RRID:AB_2205918 ), and mouse anti-TWIST1 (Abcam Cat# ab50887, RRID:AB_883294 ) were incubated overnight at 4°C, followed by incubation with Alexa Fluor 633 anti-goat IgG (Thermo Fisher Scientific Cat# A-21082, RRID:AB_2535739 ), Alexa Fluor 488 anti-rabbit IgG (Thermo Fisher Scientific Cat# A32731, RRID:AB_2633280 ), or Alexa Fluor 594 anti-mouse IgG (Molecular Probes Cat# A-11005, RRID:AB_141372) for 2 h at room temperature. ..

    Confocal Microscopy:

    Article Title: The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs
    Article Snippet: .. Immunofluorescence Staining and Confocal Microscopy Immunofluorescent stainings of 4% PFA-fixed BCSCs were performed as follows: primary Abs goat anti-CXCL1 (R & D Systems Cat# AF275, RRID:AB_355288 ), rabbit anti-OPN (Abcam Cat# ab14175, RRID:AB_2194831 ), goat anti-TRAIL (Santa Cruz Biotechnology Cat# sc-6079, RRID:AB_2205918 ), and mouse anti-TWIST1 (Abcam Cat# ab50887, RRID:AB_883294 ) were incubated overnight at 4°C, followed by incubation with Alexa Fluor 633 anti-goat IgG (Thermo Fisher Scientific Cat# A-21082, RRID:AB_2535739 ), Alexa Fluor 488 anti-rabbit IgG (Thermo Fisher Scientific Cat# A32731, RRID:AB_2633280 ), or Alexa Fluor 594 anti-mouse IgG (Molecular Probes Cat# A-11005, RRID:AB_141372) for 2 h at room temperature. ..

    Binding Assay:

    Article Title: Characterizing Autophagy in the Cold Ischemic Injury of Small Bowel Grafts: Evidence from Rat Jejunum
    Article Snippet: .. The binding of the antibodies to the membrane was detected by a secondary anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Santa Cruz Biotechnology goat anti hlamp 2
    Development of <t>anti-hLAMP-2</t> ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.
    Goat Anti Hlamp 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti hlamp 2/product/Santa Cruz Biotechnology
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti hlamp 2 - by Bioz Stars, 2021-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    Development of anti-hLAMP-2 ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: Development of anti-hLAMP-2 ELISA. (A) Comparison of ELISA plates coated with 0.5 and 5.0 µg/ml of recombinant hLAMP-2/GST fusion protein (FP). Plates coated with 5.0 µg/ml gave much better separation between positive and negative sera. (B) ELISA plates coated with hLAMP-2/GST FP were stored at 4°C and tested after different time points. Serial dilutions of a standard positive control serum gave similar results using plates stored for 1–33 days, but there was a considerable increase in background binding after 41 days. (C) Comparison of ELISA plates coated with two different batches of hLAMP-2/GST FP demonstrates comparable binding of serial dilutions of a standard positive control serum. (D) The standard curve derived from the results of assaying serial dilutions of the standard control serum was used to calculate anti-hLAMP-2 antibody concentrations with 100 U equating to OD of the 1:100 dilution of the positive control.

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Enzyme-linked Immunosorbent Assay, Recombinant, Positive Control, Binding Assay, Derivative Assay

    Antibodies to hLAMP-2 in patients with AAV. (A) ELISA results from patients presenting with active piFNGN/AAV from Vienna ( n =14), Groningen ( n =44), and Cambridge ( n =33). The upper limit of normal is 29 and the shaded area between 22 and 29 indicates borderline. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those without anti-hLAMP-2 antibodies are shown in green. Both ELISA and IIF assays were negative in sera in green with positive ELISA. (B) None of the 30 controls from Vienna with various types of renal disease were judged to have anti-hLAMP-2 antibodies, although 4 patients had isolated positive ELISA with negative Western blots and IIF assays. Two of the 21 SLE patients (9.5%) had anti-hLAMP-2 antibodies and an additional 2 patients had positive ELISA not confirmed by the other two assays. (C) Proportion of patients the Vienna, Groningen, and Cambridge cohorts with active piFNGN/AAV with antibodies to LAMP-2. Results are shown separately for untreated patients at presentation, patients presenting after immunosuppressive treatment had been started, and sera taken during relapse. The overall frequency of antibodies to LAMP-2 at presentation was 82% and was higher in untreated patients than those already on treatment. This difference was significant for the whole group ( P =0.0071, Fisher's exact text) and for the Groningen cohort ( P =0.0236, Fisher’s exact test).

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: Antibodies to hLAMP-2 in patients with AAV. (A) ELISA results from patients presenting with active piFNGN/AAV from Vienna ( n =14), Groningen ( n =44), and Cambridge ( n =33). The upper limit of normal is 29 and the shaded area between 22 and 29 indicates borderline. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those without anti-hLAMP-2 antibodies are shown in green. Both ELISA and IIF assays were negative in sera in green with positive ELISA. (B) None of the 30 controls from Vienna with various types of renal disease were judged to have anti-hLAMP-2 antibodies, although 4 patients had isolated positive ELISA with negative Western blots and IIF assays. Two of the 21 SLE patients (9.5%) had anti-hLAMP-2 antibodies and an additional 2 patients had positive ELISA not confirmed by the other two assays. (C) Proportion of patients the Vienna, Groningen, and Cambridge cohorts with active piFNGN/AAV with antibodies to LAMP-2. Results are shown separately for untreated patients at presentation, patients presenting after immunosuppressive treatment had been started, and sera taken during relapse. The overall frequency of antibodies to LAMP-2 at presentation was 82% and was higher in untreated patients than those already on treatment. This difference was significant for the whole group ( P =0.0071, Fisher's exact text) and for the Groningen cohort ( P =0.0236, Fisher’s exact test).

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Enzyme-linked Immunosorbent Assay, Isolation, Western Blot

    Indirect immunofluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface (ldlD/hLAMP-2H). (A) ldlD cells were transfected with full-length hLAMP-2 cDNA with a tyrosine to histidine mutation in the cytoplasmic lysosomal retrieval signal. Stable transfectants were sorted by flow cytometry for uniform expression of the transgene and stained with monoclonal (CD3) and polyclonal (932B) antibodies to hLAMP-2 generated by M. Fukuda as well as commercially available monoclonal (H4B4) and polyclonal anti-LAMP-2 antibodies (SCN17 and Abnova). All of the antibodies bound to hLAMP-2 on the surface of nonpermeabilized transfected cells (np). The commercial anti-hLAMP-2 cross-reacted with hamster LAMP-2 in transfected and untransfected cells especially after permeabilization (p). CD3 and 932B were the only antibodies that did not cross-react with hamster LAMP-2. A polyclonal antibody to rat LAMP-2 (Zymed Laboratories) and secondary antibody alone fail to detect either human or hamster LAMP-2. (B) FACS analysis of ldlD/hLAMP-2H cells and control ldlD cells stained with H4B4, a mAb to hLAMP-2 that cross-reacts with hamster LAMP-2. Surface expression of hLAMP-2 is detected only in transfected cells, whereas intracellular staining of native hamster LAMP-2 is apparent after permeabilization with saponin. (C) The sensitivity of the IIF assay for antibodies to hLAMP-2 assessed from doubling dilutions (1:50 to 1:800) of the standard positive control (Stand Co) compared with binding of monoclonal anti-hLAMP-2 antibody (H4B4; pos Co) and negative control serum (neg Co). IgG binding to ldlD/hLAMP-2H cells decreases progressively in titers > 1:100 and becomes negative at 1:400, which is 10-fold higher than the standard assay dilution of 1:40.

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: Indirect immunofluorescence on ldlD cells stably expressing hLAMP-2 on the cell surface (ldlD/hLAMP-2H). (A) ldlD cells were transfected with full-length hLAMP-2 cDNA with a tyrosine to histidine mutation in the cytoplasmic lysosomal retrieval signal. Stable transfectants were sorted by flow cytometry for uniform expression of the transgene and stained with monoclonal (CD3) and polyclonal (932B) antibodies to hLAMP-2 generated by M. Fukuda as well as commercially available monoclonal (H4B4) and polyclonal anti-LAMP-2 antibodies (SCN17 and Abnova). All of the antibodies bound to hLAMP-2 on the surface of nonpermeabilized transfected cells (np). The commercial anti-hLAMP-2 cross-reacted with hamster LAMP-2 in transfected and untransfected cells especially after permeabilization (p). CD3 and 932B were the only antibodies that did not cross-react with hamster LAMP-2. A polyclonal antibody to rat LAMP-2 (Zymed Laboratories) and secondary antibody alone fail to detect either human or hamster LAMP-2. (B) FACS analysis of ldlD/hLAMP-2H cells and control ldlD cells stained with H4B4, a mAb to hLAMP-2 that cross-reacts with hamster LAMP-2. Surface expression of hLAMP-2 is detected only in transfected cells, whereas intracellular staining of native hamster LAMP-2 is apparent after permeabilization with saponin. (C) The sensitivity of the IIF assay for antibodies to hLAMP-2 assessed from doubling dilutions (1:50 to 1:800) of the standard positive control (Stand Co) compared with binding of monoclonal anti-hLAMP-2 antibody (H4B4; pos Co) and negative control serum (neg Co). IgG binding to ldlD/hLAMP-2H cells decreases progressively in titers > 1:100 and becomes negative at 1:400, which is 10-fold higher than the standard assay dilution of 1:40.

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Immunofluorescence, Stable Transfection, Expressing, Transfection, Mutagenesis, Flow Cytometry, Cytometry, Staining, Generated, FACS, Positive Control, Binding Assay, Negative Control

    Evaluation of assays for antibodies to LAMP-2. (A) ELISA results from a panel of sera from 78 healthy controls were used to derive the mean ± SD for this group and the 95% confidence limit of the upper limit of normal for the assay, which was established at 29 U. Six controls had positive ELISA with negative Western blots and IIF assays. (B) ELISA results of the data shown in A. The upper limit of normal in the assay is 29 U. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those in which positive ELISA was not confirmed because ELISA and IIF assays were negative are in green. (C) Measurement of antibodies to hLAMP-2 by ELISA and Western blot using hLAMP-2/GST FP and IIF on ldlD/hLAMP-2H cells was compared using a panel of 41 sera selected to cover a range of positive and negative values. The panel consisted of 16 sera from patients with AAV (11 with active disease and 5 in remission), 15 controls with other renal diseases, and 10 healthy controls. The assays were graded positive (red), low positive (Western and IIF), borderline (ELISA) (orange), or negative (green). The figure illustrates the strong concordance among results from the three assays. Sera were considered to have antibodies to LAMP-2 when ≥2 assays were positive. Abbreviations: TX, renal transplant; MGN, membranous nephropathy; IgA GN, IgA nephropathy; MPGN, membranoproliferative GN; TIN, tubulointerstitial nephritis.

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: Evaluation of assays for antibodies to LAMP-2. (A) ELISA results from a panel of sera from 78 healthy controls were used to derive the mean ± SD for this group and the 95% confidence limit of the upper limit of normal for the assay, which was established at 29 U. Six controls had positive ELISA with negative Western blots and IIF assays. (B) ELISA results of the data shown in A. The upper limit of normal in the assay is 29 U. Sera confirmed to have anti-hLAMP-2 antibodies by the other two assays are in red, whereas those in which positive ELISA was not confirmed because ELISA and IIF assays were negative are in green. (C) Measurement of antibodies to hLAMP-2 by ELISA and Western blot using hLAMP-2/GST FP and IIF on ldlD/hLAMP-2H cells was compared using a panel of 41 sera selected to cover a range of positive and negative values. The panel consisted of 16 sera from patients with AAV (11 with active disease and 5 in remission), 15 controls with other renal diseases, and 10 healthy controls. The assays were graded positive (red), low positive (Western and IIF), borderline (ELISA) (orange), or negative (green). The figure illustrates the strong concordance among results from the three assays. Sera were considered to have antibodies to LAMP-2 when ≥2 assays were positive. Abbreviations: TX, renal transplant; MGN, membranous nephropathy; IgA GN, IgA nephropathy; MPGN, membranoproliferative GN; TIN, tubulointerstitial nephritis.

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot

    cDNA constructs, generation, and quality control of recombinant hLAMP-2. (A) Representation of cDNA encoding hLAMP-2A with the 28 amino acid leader peptide (LP), 347 amino acid extracellular domain, 24 amino acid transmembrane domain (TM), and 11 amino acid cytoplasmic domain (Cytopl). The two extracellular domain constructs were utilized to express soluble hLAMP-2 in E. coli (hLAMP-2/GST) and mammalian cells (hLAMP-2sol). Both contain the leader peptide but not the transmembrane domain or cytoplasmic tail. hLAMP-2sol expressed in mammalian cells results in an appropriately glycosylated soluble protein exported into the culture supernatant via the default secretory pathway in mammalian cells. The hLAMP-2 cytoplasmic tail contains the signal that directs its retrieval from the plasma membrane to lysosomes. The critical tyrosine was mutated to a histidine in hLAMP-2H (Y/H), which targets it to the plasma membrane when expressed in ldlD cells. (B) Purified hLAMP-2/GST runs as a single 65-kD band on SDS-PAGE and silver stain. Fractions of high purity were pooled and identity of hLAMP-2 was confirmed with an antibody reactive with hLAMP-2 only. (C) Purified hLAMP-2/GST (10 μg/ml) was separated by SDS-PAGE and transferred onto PVDF before probing with specific antibodies to hLAMP-2 (932b), which bound exclusively to the fusion protein. Antibody to GST (anti-GST) recognized both fusion protein and free GST. A human serum (1:100 dilution) containing anti-hLAMP-2 antibodies (Pat. 6) also bound the fusion protein, whereas serum from a healthy control (Healthy Co 50) did not. Serum from a patient with renal disease (Dis. Co 8) contained antibodies to GST. Secondary antibodies alone were negative (anti-human, anti-rabbit). (D) Sensitivity of the Western blot was assessed from doubling dilutions (1:50 to 1:400) of the standard positive control (Stand pos Co) used for all assays. This also confirmed the optimal binding/background ratio was 1:100.

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: cDNA constructs, generation, and quality control of recombinant hLAMP-2. (A) Representation of cDNA encoding hLAMP-2A with the 28 amino acid leader peptide (LP), 347 amino acid extracellular domain, 24 amino acid transmembrane domain (TM), and 11 amino acid cytoplasmic domain (Cytopl). The two extracellular domain constructs were utilized to express soluble hLAMP-2 in E. coli (hLAMP-2/GST) and mammalian cells (hLAMP-2sol). Both contain the leader peptide but not the transmembrane domain or cytoplasmic tail. hLAMP-2sol expressed in mammalian cells results in an appropriately glycosylated soluble protein exported into the culture supernatant via the default secretory pathway in mammalian cells. The hLAMP-2 cytoplasmic tail contains the signal that directs its retrieval from the plasma membrane to lysosomes. The critical tyrosine was mutated to a histidine in hLAMP-2H (Y/H), which targets it to the plasma membrane when expressed in ldlD cells. (B) Purified hLAMP-2/GST runs as a single 65-kD band on SDS-PAGE and silver stain. Fractions of high purity were pooled and identity of hLAMP-2 was confirmed with an antibody reactive with hLAMP-2 only. (C) Purified hLAMP-2/GST (10 μg/ml) was separated by SDS-PAGE and transferred onto PVDF before probing with specific antibodies to hLAMP-2 (932b), which bound exclusively to the fusion protein. Antibody to GST (anti-GST) recognized both fusion protein and free GST. A human serum (1:100 dilution) containing anti-hLAMP-2 antibodies (Pat. 6) also bound the fusion protein, whereas serum from a healthy control (Healthy Co 50) did not. Serum from a patient with renal disease (Dis. Co 8) contained antibodies to GST. Secondary antibodies alone were negative (anti-human, anti-rabbit). (D) Sensitivity of the Western blot was assessed from doubling dilutions (1:50 to 1:400) of the standard positive control (Stand pos Co) used for all assays. This also confirmed the optimal binding/background ratio was 1:100.

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Construct, Recombinant, Purification, SDS Page, Silver Staining, Western Blot, Positive Control, Binding Assay

    ANCA and anti-hLAMP-2 antibody titers in patients with AAV. (A and B) Sequential ANCA titers expressed as median and interquartile range in the 43 patients in the Groningen cohort followed for 12 months. ANCA titers decreased rapidly after the induction of treatment. The patients are separated into those who had PR3-ANCA ( n =25; A and C) and MPO-ANCA ( n =18; B and D). (C and D) Sequential titers of antibodies to hLAMP-2 measured by ELISA in the 43 patients in the Groningen cohort followed for 12 months. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. The patients are separated into those who had PR3-ANCA ( n =25) and MPO-ANCA ( n =18). Anti-hLAMP-2 antibodies became undetectable in

    Journal: Journal of the American Society of Nephrology : JASN

    Article Title: High Prevalence of Autoantibodies to hLAMP-2 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    doi: 10.1681/ASN.2011090920

    Figure Lengend Snippet: ANCA and anti-hLAMP-2 antibody titers in patients with AAV. (A and B) Sequential ANCA titers expressed as median and interquartile range in the 43 patients in the Groningen cohort followed for 12 months. ANCA titers decreased rapidly after the induction of treatment. The patients are separated into those who had PR3-ANCA ( n =25; A and C) and MPO-ANCA ( n =18; B and D). (C and D) Sequential titers of antibodies to hLAMP-2 measured by ELISA in the 43 patients in the Groningen cohort followed for 12 months. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. The patients are separated into those who had PR3-ANCA ( n =25) and MPO-ANCA ( n =18). Anti-hLAMP-2 antibodies became undetectable in

    Article Snippet: The following primary antibodies were used: monoclonal mouse anti-hLAMP-2, clone H4B4 (Developmental Studies Hybridoma Bank, University of Iowa); polyclonal rabbit ( ; Abnova, Taipei, Taiwan); goat anti-hLAMP-2 (sc-8101; Santa Cruz biotechnology, Santa Cruz, CA); and rabbit anti-rLAMP-2 (Zymed Laboratories, San Francisco, CA).

    Techniques: Enzyme-linked Immunosorbent Assay